The trial tested whether glucosamine and chondroitin used separately or in combination, and in comparison to placebo and celecoxib, are effective in reducing pain and improving functional ability in patients with knee osteoarthritis.
The results from the $14 million multi-center trial were presented at the annual scientific meeting of the American College of Rheumatology and could give hope to the 35 million Americans who suffer from osteoarthritis.
“One very significant finding of GAIT (the trial) is that the supplements actually outperformed the prescription drug for those with moderate to severe knee pain thus offering relief for those who need it most,” said Dr Jason Theodosakis, a member of the steering committee for the trial.